These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28208062)

  • 1. Nano-suspension coating as a technique to modulate the drug release from controlled porosity osmotic pumps for a soluble agent.
    Bahari LA; Javadzadeh Y; Jalali MB; Johari P; Nokhodchi A; Shokri J
    Colloids Surf B Biointerfaces; 2017 May; 153():27-33. PubMed ID: 28208062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micro-suspension coating method: a new approach in formulation and development of controlled porosity osmotic pump systems.
    Adibkia K; Hanaee J; Ghanbarzadeh S; Bahrami R; Shokri J
    Drug Res (Stuttg); 2014 Apr; 64(4):203-7. PubMed ID: 24026954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and formulation of nano-porous controlled porosity osmotic pumps (CPOPs) containing a poorly water soluble drug, glibenclamide.
    B LA; Javadzadeh Y; Jalali MB; Nokhodchi A; Shokri J
    Pak J Pharm Sci; 2019 Sep; 32(5):1979-1986. PubMed ID: 31813861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pore-formers and plasticizers on the release kinetic of diltiazem hydrochloride from the controlled porosity osmotic pumps.
    Shokri J; H Zarrintan M; Ghanbarzadeh S; Arash Z; Farahani A; Adibkia K
    Drug Res (Stuttg); 2013 Aug; 63(8):414-9. PubMed ID: 23599037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micro-porous surfaces in controlled drug delivery systems: design and evaluation of diltiazem hydrochloride controlled porosity osmotic pump using non-ionic surfactants as pore-former.
    Adibkia K; Ghanbarzadeh S; Shokri MH; Arami Z; Arash Z; Shokri J
    Pharm Dev Technol; 2014 Jun; 19(4):507-12. PubMed ID: 23763379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled porosity osmotic pumps of highly aqueous soluble drug containing hydrophilic polymers as release retardants.
    Prabakaran D; Singh P; Kanaujia P; Mishra V; Jaganathan KS; Vyas SP
    Pharm Dev Technol; 2004 Nov; 9(4):435-42. PubMed ID: 15581079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Evaluation of a Once-Daily Controlled Porosity Osmotic Pump of Tapentadol Hydrochloride.
    Thakkar HP; Pancholi N; Patel CV
    AAPS PharmSciTech; 2016 Oct; 17(5):1248-60. PubMed ID: 26677859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an osmotic pump system for controlled delivery of diclofenac sodium.
    Emara LH; Taha NF; Badr RM; Mursi NM
    Drug Discov Ther; 2012 Oct; 6(5):269-77. PubMed ID: 23229148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production and
    Ma C; Huang Z; Zhu Y; Chen X; Singh V; Huang Y; Pan X; Wu C
    Pharmazie; 2017 Sep; 72(9):511-517. PubMed ID: 29441977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel solubility-modulated granules through porosity osmotic pump for controlled carvedilol delivery.
    Song QL; Li P; Li YM
    Pharm Dev Technol; 2012; 17(6):666-76. PubMed ID: 21486184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled porosity solubility modulated osmotic pump tablets of gliclazide.
    Banerjee A; Verma PR; Gore S
    AAPS PharmSciTech; 2015 Jun; 16(3):554-68. PubMed ID: 25378281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled porosity osmotic pump for the delivery of flurbiprofen.
    Chauhan CS; Choudhury PK
    Curr Drug Deliv; 2006 Apr; 3(2):193-8. PubMed ID: 16611005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experiment on formulation and drug release behavior of porosity asymmetric membrane capsules in vitro.
    Fu HX; Li H; Zhang FZ; Zhao YZ; Wan CW; Chen MT; Jia XC; Yan L; Sun CC; Xu YY
    Drug Dev Ind Pharm; 2012 Jun; 38(6):670-8. PubMed ID: 22469006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chitosan-based controlled porosity osmotic pump for colon-specific delivery system: screening of formulation variables and in vitro investigation.
    Liu H; Yang XG; Nie SF; Wei LL; Zhou LL; Liu H; Tang R; Pan WS
    Int J Pharm; 2007 Mar; 332(1-2):115-24. PubMed ID: 17052871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Swellable elementary osmotic pump (SEOP): an effective device for delivery of poorly water-soluble drugs.
    Shokri J; Ahmadi P; Rashidi P; Shahsavari M; Rajabi-Siahboomi A; Nokhodchi A
    Eur J Pharm Biopharm; 2008 Feb; 68(2):289-97. PubMed ID: 17616378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled porosity osmotic pump system with biphasic release of theophylline.
    Bi Y; Mao S; Gan L; Li Y; Wang C; Xu N; Zheng Y; Cheng Q; Hou S
    Chem Pharm Bull (Tokyo); 2007 Nov; 55(11):1574-80. PubMed ID: 17978514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation and evaluation of controlled porosity osmotic pump for oral delivery of ketorolac.
    Dasankoppa FS; Ningangowdar M; Sholapur H
    J Basic Clin Pharm; 2012 Dec; 4(1):2-9. PubMed ID: 24808662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colon targeted delivery systems of metronidazole based on osmotic technology: development and evaluation.
    Kumar P; Singh S; Mishra B
    Chem Pharm Bull (Tokyo); 2008 Sep; 56(9):1234-42. PubMed ID: 18758093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified push-pull osmotic system for simultaneous delivery of theophylline and salbutamol: development and in vitro characterization.
    Prabakaran D; Singh P; Kanaujia P; Jaganathan KS; Rawat A; Vyas SP
    Int J Pharm; 2004 Oct; 284(1-2):95-108. PubMed ID: 15454301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and evaluation of controlled porosity osmotic pump for nifedipine and metoprolol combination.
    Kumaravelrajan R; Narayanan N; Suba V
    Lipids Health Dis; 2011 Apr; 10():51. PubMed ID: 21477386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.